Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of Natera’s ...

Please provide your email address to receive an email when new articles are posted on . Cell-free fetal antigen analyses had 100% consistency for 465 calls on antigens in which women were ...

DEAR DR. ROACH: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? -- M.N. ANSWER: When screening patients ...

Small cell lung cancer (SCLC) remains a challenging cancer type to treat effectively. While patients initially respond to chemotherapy and immunotherapies, the disease almost always returns, often ...

A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...

Non-invasive embryo genetic testing (niPGT) is a trending procedure that checks for chromosomal abnormalities without a cell ...

Please provide your email address to receive an email when new articles are posted on . Biopsies with high donor-derived cell-free DNA levels were likely to reveal antibody-mediated rejection.

Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? — M.N. Answer: When screening patients ...

Galit Meshulam-Simon is the associate director of Commercial Applications at Elegen. COVID-19 brought messenger RNA (mRNA) into the global spotlight, demonstrating its speed, flexibility, and efficacy ...